Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation
- Author:
Keun Sik HONG
1
Author Information
- Publication Type:Randomized Controlled Trial
- Keywords: Anticoagulants; Stroke; Atrial fibrillation; Acute coronary syndrome; Venous thromboembolism; Cardiovascular diseases
- MeSH: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Hand; Health Personnel; Heart Failure; Hip; Humans; Research Personnel; Rivaroxaban; Stroke; Thromboembolism; Thrombosis; Vascular Diseases; Venous Thromboembolism; Venous Thrombosis
- From:Journal of Stroke 2019;21(3):259-275
- CountryRepublic of Korea
- Language:English
- Abstract: Non-Vitamin K antagonist oral anticoagulants (NOACs) have been extensively investigated in medical conditions at high risk of venous or arterial thrombosis other than atrial fibrillation (AF), including hip or knee arthroplasty, acute venous thromboembolism (VTE), cancer-associated VTE, acute coronary syndrome (ACS), stable atherosclerotic vascular disease, chronic heart failure, and embolic stroke of undetermined source (ESUS). Two large ESUS trials failed to show the benefit of rivaroxaban or dabigatran, and large randomized controlled trial (RCT) data of NOACs are lacking for another potential candidates of patent foramen ovale-related stroke, acute ischemic stroke, and cerebral venous thrombosis. On the other hand, high quality evidences of NOACs have been compiled for VTE prophylaxis after hip or knee arthroplasty, acute VTE, cancer-associated VTE, and concomitant ACS and AF, which have been reflected in clinical practice guidelines. In addition, RCTs showed the benefit of very low dose rivaroxaban in combination with antiplatelet therapy in patients with ACS and in those with stable cardiovascular disease. This article summarizes the accumulated evidences of NOACs in cardiovascular diseases beyond AF, and aims to inform healthcare providers of optimal regimens tailored to individual medical conditions and help investigators design future clinical trials.
